The Intern At Work: Internal Medicine 279. The Rounds Table - 2025 ACC/AHA Clinical Practice Guidelines for Acute Coronary Syndrome
May 1, 2025
Dive into the latest guidelines on Acute Coronary Syndrome, focusing on revolutionary changes in antiplatelet therapy. Learn about the critical role of LDL regulation and the latest strategies for patients with NSTEMI. Discover insights into risk assessment tools and the impact of artificial intelligence in cardiology. Plus, enjoy some quirky egg cracking tips and chill music recommendations, adding fun to your listening experience!
AI Snips
Chapters
Transcript
Episode notes
Benefits of Newer Antiplatelets
- Newer antiplatelet agents like ticagrelor and prasugrel show clinical benefit over clopidogrel in ACS.
- The guideline makes clear that dual therapy is aspirin plus one of these preferred agents, reinforcing their superiority.
Dual Antiplatelet Therapy in ACS
- Use dual antiplatelet therapy for acute coronary syndrome (ACS) patients undergoing PCI.
- Prefer ticagrelor or prasugrel over clopidogrel for better outcomes in ACS patients.
Managing Bleeding Risk in Antiplatelet Therapy
- For patients at risk of GI bleeding, prescribe a PPI alongside dual antiplatelet therapy.
- Consider switching to ticagrelor monotherapy after 1 month post-PCI to reduce bleeding risk without raising major cardiovascular events.